Transcription factors are proteins that bind to specific DNA sequences, governing the transcription of genetic information from DNA to messenger RNA, ultimately controlling protein synthesis. HOXD13 specifically rises as a crucial regulatory molecule in melanoma by activating a cohort of signaling pathways that culminate in the increased delivery of oxygen and nutrients to tumors via new blood vessel formation. The study identifies that HOXD13 stimulates angiogenic pathways mediated by vascular endothelial growth factor (VEGF), semaphorin-3A (SEMA3A), and CD73—molecules long known for their diverse roles in vascular biology and tumor microenvironment modulation.

By experimentally suppressing HOXD13 activity in melanoma models, the investigators observed significant tumor shrinkage, affirming the transcription factor’s essential role in sustaining tumor viability. These results elevate HOXD13 from a mere biomarker to a potential therapeutic target. The mechanism by which HOXD13 enhances tumor survival is twofold: it promotes the angiogenic supply lines required for tumor metabolism and simultaneously shields tumors from immune system assaults.

Intriguingly, melanoma patients exhibiting elevated HOXD13 activity manifested a marked reduction in circulating cytotoxic T lymphocytes, the immune cells accountable for recognizing and destroying cancer cells. Additionally, the infiltration of these T cells into tumor tissue was drastically diminished in such patients. This suggests that HOXD13 mediates immune evasion by creating a hostile intratumoral environment that hinders effective immune surveillance and response.

Delving deeper into immunosuppressive mechanisms, the research elucidated that HOXD13 upregulates CD73 expression, an ectoenzyme that catalyzes the production of extracellular adenosine. This metabolite exerts powerful immunosuppressive effects by dampening T cell activation and preventing their migration into tumor sites. The rampant accumulation of adenosine effectively acts as an immunological “cloak” for melanoma, stalling cytotoxic attacks and facilitating uninterrupted cancer growth.

When HOXD13 was inhibited, there was a resurgent infiltration of cytotoxic T cells within tumors, underscoring the transcription factor’s role as a master regulator of both the vascular and immune landscapes of melanoma. These insights position HOXD13 at the crossroads between angiogenesis and immune evasion, revealing a dual-axis vulnerability ripe for therapeutic exploitation.

The study’s senior investigator, Dr. Eva Hernando-Monge, emphasizes the translational potential of these findings, advocating for combinatorial therapeutic strategies targeting both angiogenic pathways and adenosine receptor signaling. Such dual blockade could dismantle the tumor’s vascular support and immunoprotective shield simultaneously, resulting in more effective melanoma control.

Currently, clinical trials are investigating the safety and efficacy of VEGF receptor inhibitors and adenosine receptor antagonists in melanoma and other cancers, including studies combining these agents with immunotherapies. The NYU team envisions future trials specifically designed to assess the impact of dual inhibition in patients whose tumors exhibit high HOXD13 expression, aiming to convert these promising preclinical discoveries into tangible clinical benefits.

Beyond melanoma, there is a compelling rationale to explore whether HOXD13’s co-regulatory network extends to other malignancies such as glioblastomas, sarcomas, and osteosarcomas, where aberrant HOXD13 expression has also been reported. If so, this could herald a new frontier in broad-spectrum cancer therapeutics targeting developmental transcriptional programs co-opted by tumors.

The investigators conducted comprehensive analyses of tumors from over 200 melanoma patients spanning the United States, Brazil, and Mexico, identifying HOXD13 among the most prominently upregulated factors intertwined with both angiogenic and immune evasion pathways. Further mechanistic studies employing mouse models and human melanoma cell lines firmly established that HOXD13 modulates multiple complementary pathways, fostering tumor growth and triggering mechanisms to evade immune destruction.

Inhibitory experiments targeting HOXD13 directly, as well as downstream effectors VEGF and adenosine, validated the centrality of this transcription factor in melanoma maintenance. These results chart a path forward for innovative therapeutic regimens, potentially integrating genetic, vascular, and immunological interventions to surmount melanoma’s notorious resistance to treatment.

This landmark research was supported by a series of significant grants from the National Institutes of Health, along with funding from the Melanoma Research Foundation, Melanoma Research Alliance, the United Kingdom Medical Research Council, Brazilian National Council for Scientific and Technological Development, and the Wellcome Trust. The collaborative effort also spanned institutions in Mexico and Brazil, highlighting the global importance and multidisciplinary nature of this endeavor.

NYU Langone Health continues to be at the forefront of cancer research innovation, leveraging its expansive clinical and research capabilities to unravel complex molecular underpinnings of cancer and translate findings into new life-saving therapies. The discovery of HOXD13’s multifaceted role in melanoma stands as a testament to the power of integrative biomedical research in addressing one of the most challenging cancers.

In sum, this study spotlights HOXD13 as a linchpin factor orchestrating pro-tumorigenic angiogenesis and immune evasion in melanoma. By dissecting the molecular choreography through which HOXD13 regulates VEGF, SEMA3A, and CD73 pathways, the work opens new avenues for targeted therapies designed to cripple melanoma’s growth and immune resistance. The prospect of tailored interventions informed by HOXD13 status holds promise to redefine melanoma treatment and improve patient outcomes worldwide.

Subject of Research: Human tissue samples

Article Title: A targetable developmental program co-regulates angiogenesis and immune evasion in melanoma

News Publication Date: 30-Jan-2026

Web References: 10.1158/2159-8290.CD-24-1853

Keywords: Melanoma, transcription factors, angiogenesis, immune evasion, HOXD13, VEGF, CD73, adenosine, cytotoxic T cells

Long non-coding RNAs, a category of RNA molecules that do not encode proteins, have emerged as pivotal regulators within the cancer genomics landscape. These molecules play multifaceted roles that encompass gene expression regulation, chromatin remodeling, and even direct interaction with proteins involved in crucial cellular processes. In ovarian cancer, lncRNAs have been found to influence tumor growth, invasion, and metastasis, shedding light on their potential as both biomarkers and therapeutic targets.

A key focus of Abuarqoub et al.’s research is the interplay between lncRNAs and VEGF, a well-known angiogenic factor that promotes the formation of new blood vessels, a process essential for tumor growth and metastasis. The study posits that specific lncRNAs may regulate the expression of VEGF, thereby influencing ovarian cancer’s aggressiveness and progression. The relationship between lncRNAs and VEGF represents a critical axis in understanding ovarian cancer biology, as VEGF remains a significant factor contributing to the disease’s poor prognosis.

Notably, the evaluation of lncRNA expression profiles in ovarian cancer tissues indicates significant dysregulation when compared to normal ovarian tissues. This dysregulation often correlates with clinical outcomes, suggesting a prognostic role for lncRNAs in this disease. By identifying specific lncRNAs that are upregulated in ovarian cancer, researchers may pave the way for new biomarkers that can stratify patients based on their likely response to therapies, thus personalizing treatment approaches.

Additionally, the role of lncRNAs in modulating the tumor microenvironment cannot be overlooked. Abuarqoub et al. explore how lncRNAs may interact with immune cells within the ovarian cancer microenvironment, potentially shaping immune responses to tumors. This area of research is particularly pertinent given the increasing emphasis on immunotherapy in cancer treatment, where understanding the interplay between tumor cells and immune system components could lead to more effective strategies.

The therapeutic potential of targeting lncRNAs is another critical aspect discussed in the study. Their unique properties offer opportunities for innovative therapeutic approaches, including the development of lncRNA-targeting small molecules and RNA-based therapeutics like antisense oligonucleotides. Such strategies could restore normal lncRNA function or inhibit the activity of oncogenic lncRNAs, potentially leading to reduced tumor growth and enhanced chemotherapy efficacy.

Furthermore, exploring the mechanisms of how lncRNAs influence VEGF expression may also unveil novel therapeutic targets in ovarian cancer. By dissecting the pathways through which lncRNAs modulate VEGF signaling, researchers could identify specific interventions that disrupt these pathways, thereby hindering the tumor’s capacity to induce angiogenesis. This could represent a groundbreaking shift in treatment paradigms, directing focus towards molecular targets previously deemed non-druggable.

As the research community continues to unravel the complex interactions between lncRNAs, VEGF, and ovarian cancer, the implications for clinical practice are profound. There exists a pressing need for clinical trials that assess the efficacy of lncRNA-targeted therapies alongside existing treatment modalities. If successful, this could significantly change the landscape of how ovarian cancer is treated, moving towards more synergistic combinations of therapies aimed at both the genetic and environmental factors that contribute to the disease.

Education of patients and oncologists about the role of lncRNAs in ovarian cancer is also crucial. As knowledge of this field expands, patients can be better informed about their disease and potential treatment options, fostering a more collaborative environment in oncology. This empowerment can lead to improved adherence to treatment protocols and active participation in clinical trials that might lead to advancements in the management of ovarian cancer.

In conclusion, the exploration of lncRNAs and their relationship with VEGF offers a promising frontier in our understanding and treatment of ovarian cancer. Abuarqoub et al.’s research underscores the critical need to further investigate these molecular players. As researchers continue to examine the nuances of lncRNA function and their therapeutic implications, the potential to realize more effective interventions in ovarian cancer becomes ever more attainable, bringing hope to countless patients affected by this challenging disease.

As the landscape of cancer treatment evolves, integrating findings from studies such as this will be paramount in ensuring that advancements in knowledge translate into tangible benefits for patients. The road ahead is undoubtedly promising, but it requires a united effort from researchers, clinicians, and patients alike to unlock the full potential of these biomolecular discoveries.

Subject of Research: Long non-coding RNAs and VEGF in ovarian cancer.
Article Title: Long non-coding RNAs and VEGF in ovarian cancer: mechanisms and therapeutic potential.
Article References:

Abuarqoub, A.H., Abdulsahib, W.K., Jyothi, S.R. et al. Long non-coding RNAs and VEGF in ovarian cancer: mechanisms and therapeutic potential.
J Ovarian Res (2025). https://doi.org/10.1186/s13048-025-01909-7

Image Credits: AI Generated
DOI:
Keywords: Ovarian Cancer, Long Non-Coding RNAs, VEGF, Molecular Mechanisms, Therapeutic Targets, Cancer Research.

Exosomes function primarily as couriers within the TME, delivering proteins, nucleic acids, and metabolites that recalibrate the signaling networks among tumor and non-tumor cells. This vesicle-mediated dialogue profoundly impacts ferroptosis pathways, influencing whether cells succumb to or survive oxidative death. Ferroptosis, characterized by the overwhelming accumulation of lipid peroxides and reactive iron, has become recognized as a pivotal determinant in cancer cell fate and immune cell function. The ways in which exosomes modulate ferroptosis have implications that extend well beyond cell-intrinsic outcomes, contributing decisively to tumor metastasis.

Metastasis, the dissemination of malignant cells to distant organs, remains the principal cause of cancer-related mortality worldwide. Intriguingly, evidence underscores the role of exosomes in pre-conditioning remote tissues to form pre-metastatic niches—a preparatory landscape that supports cancer cell colonization. Exosomal cargoes from cancer and stromal cells within the TME enact a series of molecular events that promote vascular permeability, immune suppression, and metabolic rewiring, all of which facilitate metastatic seeding. Notably, exosomes derived from nasopharyngeal carcinoma (NPC) cells release macrophage migration inhibitory factor (MIF), which reprograms macrophage ferroptosis and encourages their polarization towards a pro-tumorigenic M2 phenotype. This dual role—protecting certain immune cells from death while fostering immunosuppressive behavior—illustrates the nuanced interplay at work.

Additionally, hepatocellular carcinoma (HCC)-derived exosomes delivering miR-142-3p highlight a distinct mechanism whereby ferroptosis is induced in M1 macrophages, dampening their antitumor activities and aiding tumor invasion. This immunosuppressive orchestration extends further as platelet-derived extracellular vesicles elevate integrin β3 expression in NPC cells, which suppresses SLC7A11, fostering ferroptosis resistance within tumor cells and enabling bloodstream-mediated metastasis. Collectively, these insights illustrate how exosome-mediated regulation of ferroptosis within immune and tumor cells orchestrates a permissive milieu for the metastatic cascade.

The immunosuppressive dimensions of ferroptosis regulation introduce another layer of complexity in tumor-immune system dynamics. Ferroptosis sustains a delicate balance, where protective mechanisms in immunosuppressive cell types such as M2 macrophages, Tregs, and tumor-infiltrating neutrophils hinge on glutathione peroxidase 4 (GPX4) activity to prevent lipid peroxidation. Disrupting these defenses through ferroptosis induction can eliminate suppressive immune cells, unleashing antitumor responses. Paradoxically, ferroptosis can also impair effector immune populations, including CD8+ T cells, natural killer cells, and dendritic cells, weakening the immune system’s ability to fight tumors. The dichotomous nature of ferroptosis in immunity reveals a complex regulatory network that cancer cells exploit to evade destruction.

Increasingly, exosomes have emerged as critical modulators at this immunological crossroads. For example, NPC- and colorectal cancer (CRC)-derived exosomes inhibit ferroptosis in macrophages, skewing polarization towards immunosuppressive states that favor tumor progression. Similarly, cancer-associated fibroblast (CAF)-derived exosomes can elevate the labile iron pool in natural killer (NK) cells, inducing ferroptosis and consequently diminishing their cytotoxic capacity against tumors. These vesicle-mediated ferroptosis interactions substantially contribute to the establishment of an immunosuppressive TME, underscoring exosomes as pivotal agents in cancer immune evasion.

Beyond modulating immune landscapes, exosomes wield significant influence over tumor drug resistance—a formidable barrier in cancer therapy. Traditional resistance mechanisms involve alterations in drug transporters, target mutations, and adaptive signaling changes. Yet, emerging research illuminates the roles of exosome-mediated ferroptosis pathways in counteracting therapy efficacy. Exosomal transfer of regulatory RNAs and proteins affects ferroptotic sensitivity in cancer cells, thereby shaping their response to chemotherapy and radiotherapy. This revelation invites reconsideration of therapeutic strategies that integrate ferroptosis modulation.

A prime example includes CAF-derived exosomal miR-522, which impedes ferroptosis in gastric cancer cells by downregulating arachidonic acid lipoxygenase 15 (ALOX15), diminishing lipid ROS accumulation. This cascade reduces sensitivity to paclitaxel and cisplatin, two cornerstone chemotherapeutics. Contrarily, the long noncoding RNA DACT3-AS1, also secreted by CAFs, has demonstrated ferroptosis-promoting effects via the miR-181a-5p/SIRT1 axis, enhancing oxaliplatin sensitivity. The interplay between ferroptosis inhibitors and promoters via exosomal transfer illustrates the complexity of chemoresistance phenotypes.

In pancreatic cancer, the development of gemcitabine resistance is similarly tied to exosomal signaling. CAF-secreted miR-3173-5p suppresses acyl-CoA synthetase long-chain family member 4 (ACSL4), a driver of ferroptosis, to bolster chemoresistance. Moreover, pancreatic cancer cell-derived exosomes containing medium-chain acyl-CoA dehydrogenase (ACADM) phenotypically correlate with gemcitabine sensitivity, linking fatty acid metabolism alterations to ferroptosis evasion. Therapeutically, silencing ACADM enhances gemcitabine efficacy, emphasizing the translational potential of targeting ferroptosis regulators within exosomal cargo.

Lung cancer models reveal further insights where exosomes from cisplatin-resistant cells are enriched in miR-4443, which suppresses ferroptosis regulator FSP1 via inhibition of m6A RNA modification pathways. This exosome-mediated epigenetic modulation fosters ferroptosis resistance, propagating acquired chemoresistance. Targeting this axis, either by inhibiting exosome secretion or miR-4443 function, offers promising avenues to overcome treatment failure.

Interestingly, adipocyte-derived exosomes also contribute to chemotherapy resistance, notably in colorectal cancer. These exosomes release the microprotein MTTP, influencing the PRAP1/ZEB1 axis to elevate GPX4 while reducing ACSL4 expression. This suppresses lipid ROS generation, dampens ferroptosis, and promotes oxaliplatin resistance. The feedback amplification triggered by chemotherapy-induced MTTP upregulation creates a reinforcing loop exacerbating drug resistance, further complicating treatment landscapes.

Radiotherapy resistance also emerges under the influence of exosomes. Hypoxic conditions characteristic of solid tumors induce lung cancer cells to secrete exosomes bearing high levels of ANGPTL4. This protein amplifies expression of key ferroptosis-regulatory proteins such as GPX4, SLC11A7, and FTH4, mitigating lipid peroxidation and iron-dependent cell death pathways. The result is enhanced radioprotection for tumor cells, underscoring the multifaceted roles of exosomes in therapeutic resistance beyond chemotherapy.

Collectively, this growing body of evidence situates exosome-mediated ferroptosis regulation as a central axis in cancer progression, immune suppression, metastasis, and treatment resistance. The intricate interplay between vesicle cargoes, iron metabolism, lipid peroxidation, and cellular phenotypes forms a sophisticated regulatory network that tumor cells exploit. Therapeutically targeting exosome biogenesis, release, or cargo content to modulate ferroptosis presents an innovative and promising frontier in overcoming the pervasive challenges of cancer treatment.

Future directions beckon integration of ferroptosis induction strategies with immunotherapy and conventional modalities, potentially unlocking synergistic effects. Additionally, monitoring exosomal markers of ferroptosis regulators may serve as liquid biopsy candidates, offering predictive insights into metastasis risk and drug responsiveness. As the field advances, a deeper mechanistic understanding of exosome-ferroptosis crosstalk in specific cancer types will be critical for designing precision medicine approaches.

In essence, the emerging paradigm positions exosomes not merely as passive carriers but as active architects of the tumor microenvironment, leveraging ferroptosis pathways to stymie immune defenses, foster metastatic spread, and blunt therapeutic efficacy. This conceptual shift invites a reassessment of cancer biology through the lens of intercellular vesicle exchange, heralding novel diagnostic and therapeutic breakthroughs.

Subject of Research:
Exosome-mediated regulation of ferroptosis within the tumor microenvironment and its impact on cancer progression, metastasis, immunosuppression, and drug resistance.

Article Title:
Exosome-mediated ferroptosis in the tumor microenvironment: from molecular mechanisms to clinical application.

Article References:
Liu, N., Wu, T., Han, G. et al. Exosome-mediated ferroptosis in the tumor microenvironment: from molecular mechanisms to clinical application. Cell Death Discov. 11, 221 (2025). https://doi.org/10.1038/s41420-025-02484-y

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02484-y